Related references
Note: Only part of the references are listed.Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3
Ana Ruiz-Saenz et al.
CANCER RESEARCH (2018)
PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers
Q. Wang et al.
ONCOGENE (2016)
Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin
Marcia R. Campbell et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Development of small molecules targeting the pseudokinase Her3
Sang Min Lim et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum
A. Ruiz-Saenz et al.
ONCOGENE (2015)
HER2-directed therapy: current treatment options for HER2-positive breast cancer
Shahid Ahmed et al.
BREAST CANCER (2015)
Pharmacological targeting of the pseudokinase Her3
Ting Xie et al.
NATURE CHEMICAL BIOLOGY (2014)
The ErbB/HER family of protein-tyrosine kinases and cancer
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation
Christian Mirschberger et al.
CANCER RESEARCH (2013)
Assessing HER2 amplification by IHC, FISH, and real-time polymerase chain reaction analysis (real-time PCR) following LCM in formalin-fixed paraffin embedded tissue from 40 women with ovarian cancer
Thore Hillig et al.
APMIS (2012)
A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines
Edith Blackburn et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
Joan T. Garrett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
Kimberly L. Blackwell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver
Dhara N. Amin et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies
M. Toi et al.
BRITISH JOURNAL OF CANCER (2009)
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
M. Scaltriti et al.
ONCOGENE (2009)
Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3
Natalia Jura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer
H. J. Burstein et al.
ANNALS OF ONCOLOGY (2008)
A central role for HER3 in HER2-amplified breast cancer:: implications for targeted therapy
Si Tuen Lee-Hoeflich et al.
CANCER RESEARCH (2008)
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
M. M. Moasser
ONCOGENE (2007)
Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland
Giorgio Cornolti et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2007)
Timeline - Insights from transgenic mouse models of ERBB2-induced breast cancer
Josie Ursini-Siegel et al.
NATURE REVIEWS CANCER (2007)
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Natalia V. Sergina et al.
NATURE (2007)
Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers
L Bizari et al.
CANCER GENETICS AND CYTOGENETICS (2006)
Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer
Andreea Nistor et al.
BMC CLINICAL PATHOLOGY (2006)
Reliability and discriminant validity of HER2 gene quantification and chromosome 17 aneusomy analysis by real-time PCR in primary breast cancer
PJ Lamy et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2006)
Amplification of c-erbB2 oncogene - A maior prognostic indicator in uterine serous papillaty carcinoma
AD Santin et al.
CANCER (2005)
HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy
K Junker et al.
LUNG CANCER (2005)
ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma
H Lassus et al.
GYNECOLOGIC ONCOLOGY (2004)
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
T Holbro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
HercepTest: HER2 expression and gene amplification in non-small cell lung cancer
G Cox et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Share Paper
